A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 78 700 KRW -1.13% Market Closed
Market Cap: 3.8T KRW

EV/EBITDA
Enterprise Value to EBITDA

-51.7
Current
-26.5
Median
4.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-51.7
=
Enterprise Value
3.7T KRW
/
EBITDA
-71.8B KRW
EBITDA Growth EV/EBITDA to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/EBITDA: 15.5
Negative Multiple: -51.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 262.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -653.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
106.6
2-Years Forward
EV/EBITDA
-194.8
3-Years Forward
EV/EBITDA
52.5